InterventionsHumans

Dual Therapy With Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Is Associated With Improved Outcomes in Patients With Heart Failure: A Real-World Propensity-Matched Cohort Study

AHA Scientific Sessions 2025 Abstract

The paper

Rahmani AR, Wong R, Tajerian A et al.

AHA Scientific Sessions 2025 Abstract · 3 Nov 2025

Presented at AHA Scientific Sessions 2025 · Abstract 4367733

doi.org/10.1161/circ.152.suppl_3.4367733

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
ARNI links to lower osteoporosis risk in heart failure
Internal and Emergency Medicine · 4 Oct 2026